Matthew Kalnik | Chief Executive Officer
Antidote Therapeutics

Matthew Kalnik, Chief Executive Officer, Antidote Therapeutics

Matthew (Matt) is the founder of Antidote Therapeutics and serves as the Company’s CEO. Matt has been part of the biotechnology industry for over 25 years and has experience in senior R&D and business development roles leading multi-disciplinary teams in drug discovery and drug development. Prior to founding Antidote, Matt was a Senior Vice President and Officer, Strategic Planning & Business Operations at Nabi Pharmaceuticals, central to bringing NicVAX from Phase 2 to Phase 3. He has also served as Senior Director, Development Technology at Daiichi Medical Research and Chief Business Officer & Senior Vice President, Business Development and Licensing at Genaissance (Allergan). Earlier, Matt was the Executive Director, Emerging Technology at Pfizer and Executive Director, Macromolecular Structure and Design at Biosym (Dassault). He holds a Ph.D. in Biochemistry & Molecular Biophysics from Columbia University and conducted his post-doctoral fellowship at the Department of Molecular Biology at The Scripps Research Institute, La Jolla, CA.

Appearances:



World Orphan Drug Congress USA 2019 - Day 1 @ 16:30

Pitch 16: First-in-class nicotine-blocker in development for the treatment of Buerger’s Disease: ATI-1013, a human anti-nicotine monoclonal antibody

last published: 20/Mar/19 21:45 GMT

back to speakers